Vitae Pharmaceuticals Inc. shares (NASDAQ:VTAE) picked up slightly Friday, gaining 46 cents, to close at $9.11, after soaring as high as $12.25, on positive top-line data from a phase I study in which an early stage experimental Alzheimer's disease (AD) therapy it co-developed with Boehringer Ingelheim GmbH reduced amyloid beta levels in cerebral spinal fluid (CSF) by more than 80 percent. Boehringer now will run additional phase I studies of the beta secretase (BACE) inhibitor, including a multiple-rising-dose trial expected to report data in the first half of 2015.